Table 1.
Basic study and patient characteristics.
| Authors | Country | Study Design | Type of Patients Evaluated | No. of Patients Evaluated with 2-[18F]FDG PET/CT | Mean Age | Male % | Type of COVID-19 Vaccine (Manufacturer) | 2-[18F]FDG PET/CT after First Dose of COVID-19 Vaccine | 2-[18F]FDG PET/CT after Second Dose of COVID-19 Vaccine | Time between COVID-19 Vaccination and PET/CT Scan (Days) |
|---|---|---|---|---|---|---|---|---|---|---|
| Adin et al. [10] | USA | R | Patients with previous recent COVID-19 vaccination who underwent 2-[18F]FDG PET/CT for oncological or other indications | 68 | 75 | 47% | mRNA vaccine (Moderna and Pfizer) | 41 (60%) | 27 (40%) | 1–47 |
| Bernstine et al. [11] | Israel | R | Patients with previous recent COVID-19 vaccination who underwent 2-[18F]FDG PET/CT for oncological indications | 650 | 69 | 46% | mRNA vaccine (Pfizer) | 394 (61%) | 256 (39%) | NR |
| Cohen et al. [12] | Israel | R | Patients with previous recent COVID-19 vaccination who underwent 2-[18F]FDG PET/CT for oncological or other indications | 728 | 69 | 43% | mRNA vaccine (Pfizer) | 346 (48%) | 382 (52%) | NR |
| Cohen et al. [13] | Israel | R | Patients with previous recent COVID-19 vaccination who underwent 2-[18F]FDG PET/CT for evaluation of hematological malignancy | 137 | 68.5 | 55% | mRNA vaccine (Pfizer) | 51 (37%) | 86 (63%) | 5–30 |
| Eifer et al. [14] | Israel | R | Patients with previous recent COVID-19 vaccination who underwent PET/CT with several radiotracers for oncological or other indications | 377 | 67 | 51% | mRNA vaccine (Pfizer) | 301 (80%) | 76 (20%) | 1–34 |
| Eshet et al. [15] | Israel | R | Patients with previous COVID-19 vaccination who underwent 2-[18F]FDG PET/CT for oncological or other indication beyond 6 weeks after vaccination | 169 | 65 | 51% | mRNA vaccine (Pfizer) | 0 | 169 (100%) | 42–71 |
| Schroeder et al. [16] | USA | R | Patients with previous recent COVID-19 vaccination who underwent 2-[18F]FDG or radiolabeled choline PET/CT for oncological indications | 54 | 76 | 64% | mRNA vaccine (Moderna and Pfizer) | NR | NR | 1–42 |
| Shin et al. [17] | Korea | R | Healthy subjects with previous recent COVID-19 vaccination who underwent 2-[18F]FDG PET/CT for cancer screening | 31 | 45 | 35% | Adenovirus-vectored vaccine (AstraZeneca) | NR | NR | 1–29 |
| Skawran et al. [18] | Switzerland | R | Patients with previous recent COVID-19 vaccination who underwent 2-[18F]FDG PET/CT for oncological indications | 140 | 67 | 72% | mRNA vaccine (Moderna and Pfizer) | 48 (34%) | 92 (66%) | 0–48 |
Legend: 2-[18F]FDG = fluorine-18 fluorodeoxyglucose; mRNA = messenger ribonucleic acid; NR = not reported; PET/CT = positron emission tomography/computed tomography; R = retrospective.